Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 9/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | F9 | P00740 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464620 | 0.91 | BTK (0.32) | IGF1RTNK2BTKDHODHF9 | |
| SCHEMBL2457285 | 0.90 | IGF1R (0.35) | IGF1RTNK2F9F10PDE10A | |
| SCHEMBL2460120 | 0.90 | IGF1R (0.35) | IGF1RTNK2DHODHF9F10 | |
| SCHEMBL2459675 | 0.88 | F9 (0.36) | IGF1RTNK2F9F10PDE10A | |
| SCHEMBL2460214 | 0.86 | IGF1R (0.37) | IGF1RTNK2BTK | |
| SCHEMBL2460636 | 0.83 | IGF1R (0.39) | IGF1RTNK2F9F10PDE10A | |
| SCHEMBL2460659 | 0.82 | IGF1R (0.47) | IGF1RTNK2PDE10AMAOB | |
| SCHEMBL2459711 | 0.82 | IGF1R (0.41) | IGF1RTNK2F9F10PDE10A | |
| SCHEMBL2460823 | 0.82 | MMP1 (0.35) | IGF1RTNK2DHODHF9F10 | |
| SCHEMBL2458683 | 0.81 | IGF1R (0.37) | IGF1RTNK2PDE10AMRGPRX4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | claimed |
| JP-2007509060-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | claimed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885TNK2 760/4885BTK 97/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885TNK2 760/4885BTK 97/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885TNK2 760/4885BTK 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.